Reported results
- CASGEVY generated $99 million in revenue for the third quarter of 2026.
- Research and development expenses were $71.9 million for the third quarter of 2026.
- Acquired in-process research and development expenses were $11.7 million for the third quarter of 2026.
- General and administrative expenses were $17.9 million for the third quarter of 2026.
- Collaboration expense, net, was $41.3 million for the third quarter of 2026.
- Net loss was $111.4 million for the third quarter of 2026.
Price and volatility reaction
The stock moved 0.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 49.99 | 2026-11-02 |
| Close after release | 49.99 | 2026-11-03 |
| Realised move | 0.0% | close to close |
| 30d ATM IV change | -4.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-02 (8-K, Item 2.02). Read the original filing on sec.gov.
